FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Cidofovir Injection
Status: Discontinuation
»Therapeutic Categories: Antiviral; Pediatric

Gilead Sciences, Inc. (Revised 07/31/2014)

Company Contact Information:
Gilead Medical Information (1-800-445-3235) [Option 2], Monday to Friday 8:00 a.m. to 5:00 p.m. Pacific Time.

Presentation Posting Date Related Information
VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion, is supplied as a non-preserved solution in single-use clear glass vials as follows: 375 mg in a 5 mL vial in a single-unit carton (NDC 61958-0101-1) 07/31/2014 Discontinuation of the manufacture of the drug. Due to a decreasing incidence of CMV retinitis in adults with AIDS, Gilead Sciences, Inc. (Gilead) has discontinued the marketing of Vistide (cidofovir injection) 75 mg/mL. Physicians can continue to use alternative medicinal products which are available to treat patients with CMV retinitis or access cidofovir injection through generic manufacturers.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English